David Moskowitz

Investment Team
San Francisco, CA
[overview]

David focuses on the Bio-IT space.

Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics. His research focused on the development of statistical and machine learning approaches for analyzing genomics data, and the characterization of epigenetic changes associated with aging in T cells.

Previously, David was a Bioinformatic Analyst at Einstein College of Medicine, where he worked on the genetics of aging and human disease. He performed his undergraduate studies in Computational Biology at Brown University.

[q&a]
Posts
Aug 3, 2020

8VC’s Investment in Mantra Bio

Paul Ehrlich, one of the forefathers of modern medicine, famously proposed the idea of a “magic bullet” that would selectively kill pathogens while sparing the body. His research led to the first drug for syphilis and established the chemistry-driven paradigm of therapeutics that would persist for the next 70 years. Unfortunately, it turned out that there is no simple way to achieve arbitrary targeting of cytotoxic chemical compounds, and these magic bullet treatments proved difficult to reproduce. The lack of precision delivery presents pharma with a double-edged sword: higher doses with elevated toxicity, or lower doses that are potentially inefficacious.

Posts
Aug 3, 2020

8VC’s Investment in Mantra Bio

Paul Ehrlich, one of the forefathers of modern medicine, famously proposed the idea of a “magic bullet” that would selectively kill pathogens while sparing the body. His research led to the first drug for syphilis and established the chemistry-driven paradigm of therapeutics that would persist for the next 70 years. Unfortunately, it turned out that there is no simple way to achieve arbitrary targeting of cytotoxic chemical compounds, and these magic bullet treatments proved difficult to reproduce. The lack of precision delivery presents pharma with a double-edged sword: higher doses with elevated toxicity, or lower doses that are potentially inefficacious.

Posts
News
Jun 18, 2020

Announcing Our Investment in Orca Bio

Every year in America, roughly 23,000 people undergo a Bone Marrow Transplant (BMT). These procedures are typically last-line interventions to save cancer patients. When successful, the therapy is often curative.

Posts
News
Jun 18, 2020

Announcing Our Investment in Orca Bio

Every year in America, roughly 23,000 people undergo a Bone Marrow Transplant (BMT). These procedures are typically last-line interventions to save cancer patients. When successful, the therapy is often curative.

Posts
May 13, 2020

8VC’s Investment in Unlearn.AI

Imagine you have an incurable disease — maybe Alzheimer’s or multiple sclerosis. Though you might be willing to take a chance on science, you would nonetheless face a difficult decision in choosing whether to volunteer for a clinical trial.

Posts
May 13, 2020

8VC’s Investment in Unlearn.AI

Imagine you have an incurable disease — maybe Alzheimer’s or multiple sclerosis. Though you might be willing to take a chance on science, you would nonetheless face a difficult decision in choosing whether to volunteer for a clinical trial.

[content]